tradingkey.logo

Amgen Inc

AMGN
341.110USD
+6.810+2.04%
終値 11/25, 16:00ET15分遅れの株価
183.69B時価総額
26.22直近12ヶ月PER

Amgen Inc

341.110
+6.810+2.04%

詳細情報 Amgen Inc 企業名

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Amgen Incの企業情報

企業コードAMGN
会社名Amgen Inc
上場日Jun 17, 1983
最高経営責任者「CEO」Mr. Robert A. (Bob) Bradway
従業員数28000
証券種類Ordinary Share
決算期末Jun 17
本社所在地One Amgen Center Drive
都市THOUSAND OAKS
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号91320-1799
電話番号18054471000
ウェブサイトhttps://www.amgen.com/
企業コードAMGN
上場日Jun 17, 1983
最高経営責任者「CEO」Mr. Robert A. (Bob) Bradway

Amgen Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-16.50%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
+12.36%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
6.66K
-14.35%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.04K
--
Dr. Michael V. Drake, M.D.
Dr. Michael V. Drake, M.D.
Independent Director
Independent Director
4.89K
+4.69%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-16.50%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Other products
1.69B
18.41%
Prolia
1.12B
12.22%
Repatha
696.00M
7.58%
Otezla
618.00M
6.73%
Enbrel
604.00M
6.58%
他の
4.45B
48.47%
地域別USD
会社名
収益
比率
US
5.93B
64.59%
ROW
2.32B
25.32%
事業別
地域別
事業別USD
会社名
収益
比率
Other products
1.69B
18.41%
Prolia
1.12B
12.22%
Repatha
696.00M
7.58%
Otezla
618.00M
6.73%
Enbrel
604.00M
6.58%
他の
4.45B
48.47%

株主

更新時刻: Sat, Nov 15
更新時刻: Sat, Nov 15
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.96%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
他の
72.25%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.96%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
他の
72.25%
種類
株主統計
比率
Investment Advisor
53.43%
Investment Advisor/Hedge Fund
19.11%
Research Firm
4.87%
Pension Fund
2.19%
Bank and Trust
1.99%
Sovereign Wealth Fund
1.18%
Insurance Company
0.63%
Hedge Fund
0.41%
Individual Investor
0.17%
他の
16.02%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
4443
450.61M
83.68%
-6.61M
2025Q2
4453
451.65M
83.89%
+6.94M
2025Q1
4519
453.49M
84.33%
+5.91M
2024Q4
4466
443.40M
82.54%
+89.78K
2024Q3
4316
438.01M
81.42%
-5.13M
2024Q2
4284
437.79M
81.61%
-4.94M
2024Q1
4192
436.25M
81.40%
-5.11M
2023Q4
4150
435.28M
81.36%
+42.25K
2023Q3
3990
429.94M
80.36%
-4.48M
2023Q2
3936
426.14M
79.65%
-4.34M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
53.86M
10%
+393.81K
+0.74%
Aug 29, 2025
State Street Investment Management (US)
29.36M
5.45%
+177.03K
+0.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.83M
5.36%
+326.43K
+1.15%
Jun 30, 2025
Capital International Investors
18.91M
3.51%
+3.78M
+24.95%
Jun 30, 2025
Capital World Investors
16.86M
3.13%
+157.99K
+0.95%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
12.89M
2.4%
+687.74K
+5.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
13.02M
2.42%
+291.27K
+2.29%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
11.01M
2.04%
-38.88K
-0.35%
Aug 31, 2025
PRIMECAP Management Company
10.63M
1.97%
-1.76M
-14.18%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
8.82M
1.64%
+91.95K
+1.05%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
VanEck Biotech ETF
12.85%
ProShares Ultra Nasdaq Biotechnology
8.38%
Invesco Nasdaq Biotechnology ETF
8.2%
iShares Biotechnology ETF
7.16%
FT Vest DJIA Dogs 10 Target Income ETF
6.87%
Invesco Dow Jones Industrial Average Dividend ETF
5.97%
Amplify Weight Loss Drug & Treatment ETF
4.82%
Invesco Biotechnology & Genome ETF
4.78%
Invesco Pharmaceuticals ETF
4.77%
iShares ESG Aware MSCI USA Value ETF
4.46%
詳細を見る
VanEck Biotech ETF
比率12.85%
ProShares Ultra Nasdaq Biotechnology
比率8.38%
Invesco Nasdaq Biotechnology ETF
比率8.2%
iShares Biotechnology ETF
比率7.16%
FT Vest DJIA Dogs 10 Target Income ETF
比率6.87%
Invesco Dow Jones Industrial Average Dividend ETF
比率5.97%
Amplify Weight Loss Drug & Treatment ETF
比率4.82%
Invesco Biotechnology & Genome ETF
比率4.78%
Invesco Pharmaceuticals ETF
比率4.77%
iShares ESG Aware MSCI USA Value ETF
比率4.46%

配当金

過去5年間の配当金総支払額は 21.35B 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
Mar 07, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Dec 12, 2022
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 08, 2023
Feb 14, 2023
Oct 28, 2022
AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 08, 2022
Nov 16, 2022
詳細を見る

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Amgen Incの上位5名の株主は誰ですか?

Amgen Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は53.86M株を保有しており、これは全体の10.00%に相当します。
State Street Investment Management (US)は29.36M株を保有しており、これは全体の5.45%に相当します。
BlackRock Institutional Trust Company, N.A.は28.83M株を保有しており、これは全体の5.36%に相当します。
Capital International Investorsは18.91M株を保有しており、これは全体の3.51%に相当します。
Capital World Investorsは16.86M株を保有しており、これは全体の3.13%に相当します。

Amgen Incの株主タイプ上位3種は何ですか?

Amgen Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.

Amgen Inc(AMGN)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Amgen Incの株式を保有している機関は4443社あり、保有株式の総市場価値は約450.61Mで、全体の83.68%を占めています。2025Q2と比較して、機関の持ち株は-0.21%増加しています。

Amgen Incの最大の収益源は何ですか?

FY2025Q2において、Other products部門がAmgen Incにとって最大の収益を生み出しており、その金額は1.69Bで、全収益の18.41%を占めています。
KeyAI